NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that the company has begun dosing patients in a U.S. phase I trial of its oral formulation of darinaparsin (ZIO-101) to treat solid tumors. The Company has also initiated patient treatment in a U.S. phase I trial of the oral formulation of indibulin (ZIO-301) in solid tumors. The Company’s strategy is to pursue oral formulations for all of their compounds as oral formulations may offer considerable advantages over infusion formulations including patient convenience, cost savings, and commercial benefit.
